← Back to Search

Behavioural Intervention

EndeavorOTC for Attention Deficit Disorder

N/A
Waitlist Available
Led By Caitlin Stamatis, PhD
Research Sponsored by Akili Interactive Labs, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Is 18 years of age or older
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, day 42, day 84
Awards & highlights
No Placebo-Only Group

Summary

"This trial aims to test a digital therapy called EndeavorOTC on university students to see if it can improve their cognitive and emotional health."

Who is the study for?
This study is for university students who may have attention issues or want to improve their cognitive functioning. Participants should be interested in trying a digital therapeutic called EndeavorOTC®.
What is being tested?
The trial is testing the effects of a digital therapy app, EndeavorOTC®, on executive and cognitive functions in college students. It aims to see if this app can help with focus, memory, and other brain skills.
What are the potential side effects?
Since EndeavorOTC® is a digital therapeutic (a type of treatment using software), it's not expected to have physical side effects like medication would. However, users might experience eye strain or headache from screen use.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, day 42, day 84
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, day 42, day 84 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adult ADHD Self-Report Scale (ASRS)
Computerized Adaptive Test, Mental Health (CAT-MH®)
General Academic Self-Efficacy scale (GASE)
+4 more
Other study objectives
System Usability Scale (SUS)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Group 2Experimental Treatment1 Intervention
Participants receive 12-week access to EndeavorOTC 6-weeks after Group 1.
Group II: Group 1Experimental Treatment1 Intervention
Participants receive immediate 12-week access to EndeavorOTC.

Find a Location

Who is running the clinical trial?

Akili Interactive Labs, Inc.Lead Sponsor
16 Previous Clinical Trials
2,013 Total Patients Enrolled
Landmark CollegeUNKNOWN
Villa Maria CollegeUNKNOWN
~42 spots leftby Dec 2025